Meeting
2022 ASCO Annual Meeting
Management of residual nonretroperitoneal disease in nonseminomatous germ-cell tumors (NSGCT).
Authors
Jennifer King
Indiana University School of Medicine, Indianapolis, IN
Jennifer King , Kenneth Kesler , Ryan Ashkar , Sandra K. Althouse , Nasser H. Hanna , Lawrence H. Einhorn , Nabil Adra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Germ Cell/Testicular Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5034)
DOI
10.1200/JCO.2022.40.16_suppl.5034
Abstract #
5034
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse.
First Author: Ahmed Bilal Khalid
Poster
2022 ASCO Genitourinary Cancers Symposium
Differentially expressed mRNA/proteins can distinguish viable germ cell tumors and teratomas from necrosis in retroperitoneal lymph node resections after chemotherapy (pcRPLND).
First Author: Tim Nestler
Poster
2018 Genitourinary Cancers Symposium
Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumor patients.
First Author: Ricardo Romao Nazario Leao
Poster
2014 Genitourinary Cancers Symposium
Surgical management of testicular cancer patients with complex postchemotherapy residual masses: Aachen University experience.
First Author: Axel Heidenreich